DDInter1729 DDInter513
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Sulindac {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Hyperglycaemia {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Triamcinolone
Triamcinolone {u} (Compound) resembles {v} (Compound) Dexamethasone
Sulindac {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Hyperglycaemia {u} (Side Effect) is caused by {v} (Compound) Fludrocortisone
Fludrocortisone {u} (Compound) resembles {v} (Compound) Dexamethasone
Sulindac {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Triamcinolone
Triamcinolone {u} (Compound) resembles {v} (Compound) Dexamethasone
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) interacts with {v} (Gene) CYB5A
CYB5A {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is downregulated by {v} (Compound) Fluocinonide
Fluocinonide {u} (Compound) resembles {v} (Compound) Dexamethasone
Sulindac {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Sulindac {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Albendazole
Albendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Dexamethasone (Compound)
Sulindac (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Triamcinolone (Compound) and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Sulindac (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Sulindac (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Triamcinolone (Compound) and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) interacts with CYB5A (Gene) and CYB5A (Gene) is upregulated by Dexamethasone (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is downregulated by Fluocinonide (Compound) and Fluocinonide (Compound) resembles Dexamethasone (Compound)
Sulindac (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Dexamethasone (Compound)
Sulindac (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Albendazole (Compound) and Albendazole may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone